READ-ONLY DIGITIZATION RESULT
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Blood · 2025-Sep-11 · PMID 40198878
Panel OS_in_patients_overall提取完成待 EXE 对齐验证
Overall survival
Figure 3. OS in patients overall. ∗HR based on stratified Cox proportional hazards model; † P value based on stratified log-rank test. ‡HR based on unstratified Cox proportional hazards model; § P value based on unstratified log-rank test. Clb, chlorambucil.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 3 | 2026-07-23T16:28:00+00:00 |